Abbonarsi

Abnormal tryptophan catabolism in diabetes mellitus and its complications: Opportunities and challenges - 13/09/23

Doi : 10.1016/j.biopha.2023.115395 
Jialiang Gao a, 1, Ting Yang a, 1, Bohan Song a, Xiaojie Ma a, Yichen Ma a, Xiaowei Lin b, , Hongwu Wang b,
a Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China 
b College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China 

Correspondence to: College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No. 10 Poyang Lake Road, Jinghai District, Tianjin 301617, PR China.College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese MedicineNo. 10 Poyang Lake Road, Jinghai DistrictTianjin301617PR China

Abstract

In recent years, the incidence rate of diabetes mellitus (DM), including type 1 diabetes mellitus(T1DM), type 2 diabetes mellitus(T2DM), and gestational diabetes mellitus (GDM), has increased year by year and has become a major global health problem. DM can lead to serious complications of macrovascular and microvascular. Tryptophan (Trp) is an essential amino acid for the human body. Trp is metabolized in the body through the indole pathway, kynurenine (Kyn) pathway and serotonin (5-HT) pathway, and is regulated by intestinal microorganisms to varying degrees. These three metabolic pathways have extensive regulatory effects on the immune, endocrine, neural, and energy metabolism systems of the body, and are related to the physiological and pathological processes of various diseases. The key enzymes and metabolites in the Trp metabolic pathway are also deeply involved in the pathogenesis of DM, playing an important role in pancreatic function, insulin resistance (IR), intestinal barrier, and angiogenesis. In DM and its complications, there is a disruption of Trp metabolic balance. Several therapy approaches for DM and complications have been proven to modify tryptophan metabolism. The metabolism of Trp is becoming a new area of focus for DM prevention and care. This paper reviews the impact of the three metabolic pathways of Trp on the pathogenesis of DM and the alterations in Trp metabolism in these diseases, expecting to provide entry points for the treatment of DM and its complications.

Il testo completo di questo articolo è disponibile in PDF.

Graphical Abstract




 : 

Abnormalities in Trp catabolism occur in DM and co-morbidities. A variety of therapeutic modalities for DM and its complications can modulate Trp catabolism.


Abnormalities in Trp catabolism occur in DM and co-morbidities. A variety of therapeutic modalities for DM and its complications can modulate Trp catabolism.ga1

Il testo completo di questo articolo è disponibile in PDF.

Highlights

Tryptophan catabolism is influenced by intestinal microorganisms.
Recent advances in abnormal tryptophan catabolism in diabetes and complications.
Some tryptophan catabolites can be used as risk markers for diabetes and complications.
Role of tryptophan metabolites in diabetes.
Tryptophan metabolism as a potential target for the treatment of diabetes and complications.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : T1DM, T2DM, GDM, , Trp, , Kyn, , 5-HT, , IR, , DN, , DPN, , DKA, , DACI, , AD, , IPA, , IDO1/2, , Tna, , ArAT, , IP, , IAld, , IAA, , skate, , IA, , fldBC, , IBD, , Ahr, , PBMC, , IL-6, , IFN-λ, , TNF, , TAM, , GF, , KO, , SPF, Tryptophan 2, KATs, , KYNA, , KMO, , 3-HK, , 3-HAA, , XA, , 3-HAAO, , QUIN, , iNOS, , TpH2, , ECs, , 5-HTRs, , Trpa1, , HFD, , Gpr35, , IS, , DNP, , DR, , NPDR, , PDR, , Sus, , ARB, , BLC, , MD, , IF, , RYGB

Keywords : Diabetes, Diabetes complications, Tryptophan, Catabolism


Mappa


© 2023  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 166

Articolo 115395- ottobre 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Targeted protein degradation for the treatment of Parkinson’s disease: Advances and future perspective
  • Roshanak Amirian, Mehdi Azadi Badrbani, Hossein Derakhshankhah, Zhila Izadi, Mohammad-Ali Shahbazi
| Articolo seguente Articolo seguente
  • A state-of-art of underlying molecular mechanisms and pharmacological interventions/nanotherapeutics for cisplatin resistance in gastric cancer
  • Jitendra Gupta, Abdulrahman T. Ahmed, Nahla A. Tayyib, Rahman S. Zabibah, Qakhramon Shomurodov, Mostafai N. Kadheim, Fahad Alsaikhan, Pushpamala Ramaiah, Lathamangeswari Chinnasamy, Saeed Samarghandian

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.